Skip to main content
SpringerLink
Log in

The ratio of late-follicular to mid-follicular phase LH concentrations efficiently predicts ART outcomes in women undergoing ART treatment with GnRH-agonist long protocol and stimulation with recombinant FSH

  • ASSISTED REPRODUCTION
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose

To establish an index to predict ART outcomes and to identify infertile patients who need LH supplementation during ovarian stimulation.

Methods

Serum LH concentrations were measured during the mid- and late-follicular phase in 86 normogonadotropic infertile patients who underwent ART treatment using GnRH-agonist long protocol with recombinant-FSH. The relationships between serum LH concentrations at both time points and ART outcomes were retrospectively analyzed, and the relationships between the ratio of late-follicular to mid-follicular LH concentrations and ART outcomes were also evaluated.

Results

There were no significant correlations between the mid- or late-follicular LH concentrations and ART outcomes. The ratio of late-follicular to mid-follicular LH concentrations <1.0 was considered the relatively LH decreased group (RD group) and ratio ≥ 1.0 was considered the relatively LH increased group (RI group). The number of usable embryos in RD group was similar to that in RI group, but the pregnancy and implantation rates in the RD group (9.7% and 5.8%) were significantly lower than those in the RI group (31.1% and 17.2%; p < 0.05).

Conclusions

Relatively decreased LH concentrations during ovarian stimulation using GnRH-agonist long protocol with rec-FSH had a negative effect on ART outcomes. Therefore, the ratio of mid- to late-follicular phase LH concentrations is suggested to be an efficient index to identify patients who might benefit from LH supplementation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wildt L, Diedrich K, van der Ven H, al Hasani S, Hubner H, Klasen R. Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotrophins. Hum Reprod. 1986;1:15–9.

    PubMed  CAS  Google Scholar 

  2. Devroy P, Mannaerts B, Smitz J, Coelingh Bennink H, Van Steirteghem A. Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotropin-releasing hormone agonist regimens. Hum Reprod. 1994;9:1064–9.

    Google Scholar 

  3. Cabrera RA, Stadtmauer L, Mayer JF, Gibbons WE, Oehninger S. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone. Fertil Steril. 2005;83:42–8. doi:10.1016/j.fertnstert.2004.06.050.

    Article  PubMed  CAS  Google Scholar 

  4. Kolibianakis EM, Collins J, Tarlatzis B, Papanikolous E, Devroy P. Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review. Hum Reprod Update. 2006;12:3–12. doi:10.1093/humupd/dmi030.

    Article  PubMed  CAS  Google Scholar 

  5. Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod. 1998;13:1788–92. doi:10.1093/humrep/13.7.1788.

    Article  PubMed  CAS  Google Scholar 

  6. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15:1003–8. doi:10.1093/humrep/15.5.1003.

    Article  PubMed  CAS  Google Scholar 

  7. Balasch J, Vidal E, Peñarrubia J, Casamitjana R, Carmona F, Creus M, et al. Suppression of LH during ovarian stimulation: analyzing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Hum Reprod. 2001;16:1636–43. doi:10.1093/humrep/16.8.1636.

    Article  PubMed  CAS  Google Scholar 

  8. Esposito MA, Barnhart KT, Coutifaris C, Patrizio P. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertil Steril. 2001;75:519–24. doi:10.1016/S0015-0282(00)01745-3.

    Article  PubMed  CAS  Google Scholar 

  9. Humaidan P, Bungum L, Bungum M, Andersen CY. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum Reprod. 2002;17:2016–21. doi:10.1093/humrep/17.8.2016.

    Article  PubMed  CAS  Google Scholar 

  10. Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: on opening study. Reprod Biomed Online. 2004;8:635–43.

    PubMed  CAS  Google Scholar 

  11. Humaidan P. To add or not to add LH: comments on a recent commentary. Reprod Biomed Online. 2006;12:284–5.

    Article  PubMed  Google Scholar 

  12. Nakagawa K, Ohgi S, Kojima R, Sugawara K, Horikawa T, Ito M, I Irahara M, Saito H. Recombinant-FSH has more effective potent than urinary human menopausal gonadotropin in ovarian hyperstimulation for ART treatment. Reprod Med Biol. 2007;6:27–32. doi:10.1111/j.1447-0578.2007.00161.x.

    Article  CAS  Google Scholar 

  13. Nakagawa K, Ohgi S, Kojima R, Ito M, Horikawa T, Irahara M, et al. Reduction of perifollicular arterial blood flow resistance after hCG administration is a good indicator of the recovery of mature oocytes in ART treatment. J Assist Reprod Genet. 2006;23:433–8. doi:10.1007/s10815-006-9087-4.

    Article  PubMed  Google Scholar 

  14. Nakagawa K, Yamano S, Moride N, Yamashita M, Yoshizawa M, Aono T. Effect of activation with Ca ionophore A23187 and puromycin on the development of human oocytes that failed to fertilize after intracytoplasmic sperm injection. Fertil Steril. 2001;76:148–52. doi:10.1016/S0015-0282(01)01839-8.

    Article  PubMed  CAS  Google Scholar 

  15. The European recombinant human LH study group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced folliclar development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 1998;83:1507–14. doi:10.1210/jc.83.5.1507.

    Article  Google Scholar 

  16. Shoham Z, Balen A, Patel A, Jacobs HS. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotorpic hypogonadism patients. Fertil Steril. 1991;56:1048–53.

    PubMed  CAS  Google Scholar 

  17. Lauoud R, Al-Jefout M, Tyler J, Ryan J, Driscoll G. A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates. Hum Reprod. 2006;21:2645–9. doi:10.1093/humrep/del219.

    Article  Google Scholar 

  18. Kol S. To add or not to add LH: consideration of LH concentration changes in individual patients. Reprod Biomed Online. 2005;11:664–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Reproductive Medicine, Department of Perinatal Medicine and Maternal Care, National Center for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo, 157-8535, Japan

    Koji Nakagawa, Shirei Ohgi, Akira Nakashima, Takashi Horikawa & Hidekazu Saito

  2. Division of Reproductive Medicine, Sugiyama Ladies Clinic, Tokyo, Japan

    Rikikazu Sugiyama

Authors
  1. Koji Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shirei Ohgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akira Nakashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takashi Horikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rikikazu Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hidekazu Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Nakagawa.

Additional information

Capsule A relative decrease in LH concentration during ovarian stimulation in a GnRH-a long protocol negatively affected the ART outcomes. This ratio can be used to identify patients who need LH supplementation.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakagawa, K., Ohgi, S., Nakashima, A. et al. The ratio of late-follicular to mid-follicular phase LH concentrations efficiently predicts ART outcomes in women undergoing ART treatment with GnRH-agonist long protocol and stimulation with recombinant FSH. J Assist Reprod Genet 25, 359–364 (2008). https://doi.org/10.1007/s10815-008-9243-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-008-9243-0

Keywords

Search

Navigation